ArticleCancer management and research2025
Modified Glasgow Prognostic Score Incorporating CRP/Albumin Ratio and LDH Levels as Prognostic Indicators in Patients with Multiple Myeloma: A Retrospective Study.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate whether integrating the CRP/Albumin Ratio (CAR) and Lactate Dehydrogenase (LDH) levels into the Modified Glasgow Prognostic Score (mGPS) enhances its prognostic accuracy in patients with multiple myeloma (MM). Patients and Methods: A single-center retrospective study was conducted on patients diagnosed with multiple myeloma (MM) at Afyonkarahisar Health Sciences University between 2017 and 2023. Demographic, clinical, and laboratory data including mGPS, CAR, LDH, and ISS staging were collected. Survival outcomes were assessed using Kaplan-Meier curves, and Cox regression models were used to determine prognostic factors. Results: Among the 130 patients, the ISS score was the strongest predictor of mortality (HR = 1.63, 95% CI: 1.27-2.09, p = 0.0001). mGPS 2 combined with LDH > 250 IU (HR = 1.96, 95% CI: 1.32-2.92) and CAR > 0.51 (HR = 1.71, 95% CI: 1.16-2.53) were independent risk factors. mGPS alone remained a consistent prognostic marker (HR = 1.42, 95% CI: 1.14-1.77). One-year survival was 50.0% in the mGPS 2 group, dropping to 30.3% at two years. The mGPS 2 + LDH > 250 IU group had the poorest survival (39.5% to 23.3%), followed by the mGPS 2 + CAR > 0.51 group (44.9% to 28.6%). Median PFS was 28.0, 47.0, and 9.0 months in mGPS0, mGPS1, and mGPS2, respectively (p < 0.001), with mGPS2 showing significantly shorter PFS. mGPS2, CAR, LDH, and their combinations were independent predictors of progression. In mGPS2, OS and PFS declined steadily over 36 months, with the lowest long term PFS in the CAR elevated subgroup. Conclusion: Integrating CAR and LDH into the mGPS offers a cost-effective and accessible approach to improve risk stratification in patients with MM. This enhanced model provides a comprehensive assessment of systemic inflammation and tumour burden, supporting its potential use in clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.